3 results
Primary objective:To compare the effect of multiple dose atazanavir/cobicistat on the multiple dose phar-macokinetics of daclatasvir with the effect of atazanavir/ritonavir on the multiple dose of daclatasvir by intra-subject comparison in healthy…
To determine the conversion rate of PR to CR (i.e. PET negativity) after a single dose of 90Y-ibritumomab tiuxetan (a dose of 14.8 MBq/kg or 0.4 mCi/kg, max 1184 MBq or 32mCi) in patients with grade 1-3a, stage II, III or IV follicular lymphoma with…
Primary Objective:• To create a population pharmacokinetic model of SARS-COV-2 neutralizing antibodies as present in ConvP.• To create a population pharmacokinetic model of SARS-COV-2 neutralizing antibodies as present in Nanogam*plusSecondary…